• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • AZ kicks off PhI trial of potential COVID-19 therapy pharmatimes
    August 26, 2020
    AstraZeneca has dosed the first participants in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) being developed for prevention and treatment of COVID-19.
Previous page 1 2 3 Next page

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service